Search results
Results from the WOW.Com Content Network
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted immunotherapy for adults in the advanced stages of hard-to-treat small cell lung ...
The U.S. health regulator on Wednesday approved the expanded use of Bristol Myers Squibb's cancer cell therapy Breyanzi for the treatment of adults with a type of blood cancer called follicular ...
(Reuters) -The U.S. Food and Drug Administration (FDA) has approved Bristol-Myers Squibb's lung cancer drug that was acquired as part of the company's $4.1 billion buyout of Turning Point ...
AOH1996 is an experimental anticancer medication which acts as a small molecule inhibitor of proliferating cell nuclear antigen (PCNA) and is in Phase I clinical trials at City of Hope as of August 2023 for the treatment of solid tumors.
Dostarlimab was approved for the treatment of endometrial cancer in both the United States and the European Union in April 2021. [5] [6] [11] [8] [12] Based on the Garnet trial, dostarlimab gained accelerated approval from the US Food and Drug Administration (FDA) in April 2021, [6] and full approval in February 2023. [7]
When blinatumomab was approved, Amgen announced that the price for the drug would be US$178,000 per year, which made it the most expensive cancer drug on the market. Merck's pembrolizumab was priced at US$150,000 per year when it launched (in September 2014). [ 15 ]
The FDA approval is based on data from a mid-stage study that showed that 58% of patients treated with Pfizer's therapy had no signs of cancer or had seen a significant decrease in cancer cells in ...
Pralsetinib was approved for medical use in the United States in September 2020. [14] [15] Dabrafenib and trametinib have been approved as tissue-agnostic drugs for solid tumors that are B-RAF positive. [16] Tissue-agnostic cancer drugs that are under development as of May 2022 include Selitrectinib (Loxo-195) and anti-ERBB3 antibodies. [7]